2014台湾美女 揭秘好身材修炼术

正2014年台湾百大性感美女排行榜新鲜出炉!DREAMGIRLS成员郭雪芙以爆棚的人气蝉联冠军,紧随其后的还有张钧甯、张景岚、谢金燕等等。看着这些女明星个个身材这么好,女孩们都很羡慕吧!想要变得更性感吗?那就赶紧跟百大美女们偷学几个瘦身妙招吧。郭雪芙身高:167cm体重:47kg郭雪芙的瘦身关键词:饮食近几年真的是郭雪芙的事业黄金期,作为DREAM GIRLS的她不仅出了团体专辑,荧屏上也是不断出佳作,人气可见一斑。今年,她又与Super Junior的金希澈     

新年寄语

流光溢彩,又是一年。《中国实用妇科与产科杂志》在全国妇产科同道的支持下,编辑部全体工作人员通力合作,顺利地完成了2007年度的编辑出版任务。值此辞旧迎新之际,向所有支持和关爱本刊发展的专家和朋友们致以新年最诚擎的问候!随着医学信息学的飞速发展,期刊作为传播载体,起着举足轻重的作用,同时也使广大编委和编辑同志深感肩负责任之重大。回顾既往,从《中国实用妇科与产科杂志》诞生至今,创刊24年,凝聚了我国妇产科几代人的心血,承蒙广大妇产科同仁诚擎的厚爱与大力文持,在各位妇产科学专家及老前辈的真诚帮助与热心指导下,通过不断汲取…     

《中国实用妇科与产科杂志》2011年各期中心内容

尊敬的妇产科同仁们:经过广泛征求本刊编委和读者的意见,2011年1~12期各期中心内容选题已经确定。欢迎大家踊跃撰文,并登录本刊网站投稿(www.zgsyz.com)。     

胎儿畸形的宫内治疗及其进展

围产医学的兴起和胎儿医学的诞生是人类在探索自然的同时也在不断探索人类自己的成果体现。对通过超声检查、羊水检测等方法产前诊断的某些胎儿畸形进行外科性干预和矫治,从而防止畸形的进一步发展、避免其对器官的发育和功能造成更大影响(甚至威胁胎儿生命),是胎儿外科的主要工作内容。胎儿外科是当今世界医学的前沿和最活跃的研究、诊疗领域之一。产前诊断畸形后终止妊娠或生后手术治疗的传统医学模式受到了严重挑战。1历史回顾胎儿外科始于上世纪60年代初,但由于当时诊疗条件(影像、麻醉、器械等)的限制,只限于初步尝试。1960年Liley[1]…     

74例经产妇分娩巨大儿的相关因素及预后分析

目的:探讨经产妇分娩巨大儿相关因素与预后的关系.方法:回顾分析2004年1月至2006年12月分娩的74例非妊娠期糖尿病,无严重内外科合并症的经产妇巨大儿资料,与随机选择的同期分娩的无合并症经产妇正常体重儿作对照分析,并与同期分娩的初产妇巨大儿比较.结果:经产妇巨大儿组平均孕龄、孕末期体重、宫高、腹围、产时及产后2小时出血量、异常产程、剖宫产率、新生儿窒息率都高于经产妇正常体重儿组,差异有显著性(P＜0.05);与初产妇巨大儿组比较,正规产检比例明显降低,过期妊娠、新生儿窒息率增加,择期剖宫产率低.结论:加强经产妇围生期管理,产前正确预测经产妇巨大儿,选择适当的分娩方式,对预防产后出血,降低母婴并发症至关重要.     

胎儿结构异常的中孕期超声筛查

1中孕期超声筛查的目的中孕期超声筛查的目的包括:检出多胞胎,确定绒毛膜和羊膜的数目。通过胎儿生物参数[双顶径(BPD)、头围(HC)、股骨长度(FL)、腹围(AC)等]的测量准确地确定孕周;检查宫颈和胎盘位置;检查子宫及附件有无异常(排除子宫肌瘤和卵巢肿瘤)等。但主要目的还是胎儿严重先天畸形的筛查[1-2]。虽然很多研究表明妊娠早期可以诊断相当多数量的胎儿畸形,但有限数目的随机对照研究显示中孕期的超声筛查仍然是不可取代的[3-4]。20世纪80年代以来,中孕期(18~23周)胎儿畸形的超声诊断已经成为欧美国家的常规[5-7]。中孕期的常规超声检…     

绝经后宫腔积脓的诊断和治疗

子宫积脓常发生于绝经后妇女.因为绝经后卵巢功能衰退,体内雌、孕激素水平低下,阴道上皮细胞糖原含量减少,阴道pH值上升,使阴道自净作用减弱,失去防御能力.宫颈纤维组织增生,腺体数目减少,宫颈管缺乏黏液栓保护,易发生上行性感染.颈管狭窄、粘连,官腔分泌物无法排出,易致官腔积血或积脓;萎缩的子宫内膜血运减少,缺乏再生和修复能力,又无周期性脱落,为细菌滞留生存提供了良好的条件.当官腔内长期放置节育器或合并有糖尿病、子宫内膜结核、子宫内膜癌、子宫颈癌等,则更易发生官腔积液、积脓….据报道,绝经后妇女宫腔积液的发生率为11.83%,官腔积脓的发生率约为0.5%.但随着年龄的增大和绝经时间的延长,发生率将逐渐增高.     

A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis

OBJECTIVE: In order to assess the endocrinological changes associated with 2 types of low-dose GnRH agonists depot as well as their clinical efficacy, we performed a randomized prospective comparison study of patients having uterine leiomyomas or endometriosis. METHODS: A prospective randomized study involving 67 patients with uterine leiomyomas or endometriosis was carried out. These patients were randomly administered either buserelin MP 1.8 mg (Group B, n = 34) or leuprolide 1.88 mg (Group L, n = 33). In each group we evaluated the symptoms of genital bleeding and hot flashes during GnRHa treatment, as well as the levels of serum LH, FSH, and estradiol 8 weeks after the start of treatment. In addition, the endometrial thickness was measured by transvaginal ultrasonography, and changes in the volume of the uterine leiomyoma or endometrial cyst at the end of treatment. The GnRHa depot was administered from 3 to 8 times, 28 days apart, in both groups. RESULTS: The incidence of menstruation-like genital bleeding 8 weeks after treatment was significantly (p < 0.01) higher in Group B. However this difference disappeared by 12 weeks after treatment. The climacteric symptom of hot flashes was found to be significantly (p < 0.01) more severe in Group L, and this tendency continued until 20 weeks after treatment. The 2 groups did not differ significantly with regard to the levels of the serum LH, FSH, and estradiol at 8 weeks after treatment or in the endometrial thickness at the end of the GnRHa treatment. In both groups, the volumes of the uterine leiomyomas were significantly (p < 0.01) lower after the treatment. In contrast, the volumes of the endometrial cysts did not decrease after administration of GnRHa in both groups. CONCLUSION: Leuprolide 1.88 induced pituitary down regulation more rapidly than buserelin MP. However the hypoestrogenic symptoms such as hot flashes were more severe in cases treated with leuprolide 1.88 than in those treated with buserelin MP. Our data confirm that the therapeutic efficacy of buserelin MP and leuprolide 1.88 are similar, with both being sufficient to treat uterine leiomyomas and endometriosis.     

左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床疗效研究

目的:探讨左炔诺孕酮宫内缓释系统(LNG-IUS)治疗子宫腺肌病(AM)的临床疗效。方法:对67例AM患者子宫内放入LNG-IUS,检测放置前、放置后1、3、6、12、24个月的月经量、痛经情况、子宫内膜厚度、子宫体积以及血清中的血红蛋白(Hb)、促卵泡生成素(FSH)、黄体生成素(LH)、雌二醇(E_2)等指标的变化。结果:放置LNG-IUS后,患者的月经量在3个月后较放置前明显减少(P0.05),痛经在放置3个月后较放置前明显减轻(P0.05),子宫内膜厚度在放置1个月后较放置前明显变薄(P0.05),子宫体积在放置1年后明显缩小(P0.05),血清Hb水平在放置6个月后较放置前明显上升(P0.05),血清FSH、LH、E_2水平放置前、后无统计学差异(P0.05)。结论:LNG-IUS能有效缓解AM患者痛经、减少月经量、改善子宫内膜厚度并在一定程度上缩小子宫体积、提高血清Hb水平,且不会影响患者卵巢功能,是治疗AM的一种有效方法。     

不同低剂量米非司酮治疗子宫腺肌病伴痛经患者的疗效研究

目的:通过比较不同低剂量米非司酮(RU486)治疗子宫腺肌病伴有痛经的疗效,以筛选合适低剂量RU486治疗子宫腺肌病伴痛经的方案。方法:选择子宫腺肌病伴痛经的68例患者,分别给予RU486每周25mg(Ⅰ组,n=33)、每天5mg(Ⅱ组,n=24)和每天2.5mg(Ⅲ组,n=11)治疗,比较观察治疗前后子宫大小、血清CA125水平、VAS评分、月经量、子宫内膜厚度以及血红蛋白含量的变化。结果:服药后3个月和6个月,3组患者的VAS评分与月经量均显著低于服药前(P0.05),血红蛋白含量显著高于服药前(P0.05)。Ⅰ组患者服药后3个月与6个月的血清CA125水平均低于服药前(P0.05),但服药后3个月和6个月的子宫体积与内膜厚度与服药前比较,差异均无显著性(P0.05)。Ⅱ组患者服药后3个月的血清CA125水平与子宫体积均显著低于服药前(P0.05),服药后6个月的血清CA125水平与子宫体积与服药前比较,差异均无显著性(P0.05),但子宫内膜厚度显著高于服药前(P0.05)。Ⅲ组患者服药后6个月的血清CA125水平与内膜厚度均显著高于服药前(P0.05),但服药后3个月和6个月的子宫体积与服药前比较,差异均无显著性(P0.05)。结论:小剂量RU486均可有效治疗子宫腺肌病患者的痛经症状,但由于RU486(25mg/周)方案服用间隔时间长且方便同时又不增加子宫内膜厚度可作为短期治疗子宫腺肌病伴痛经患者的首选。     

Prediction of the therapeutic effect of dienogest in ovarian endometrial cysts using the apparent diffusion coefficient

The purpose of this study was to investigate whether apparent diffusion coefficient (ADC) mean values can be used for predicting the treatment response in ovarian endometrial cyst patients with dienogest (DNG) administration. Eighteen patients received DNG (2?mg/day, orally) for 60 days, among whom 26 ovarian endometrial cysts were retrospectively identified. Mean ADC values of individual ovarian endometrial cysts were obtained by ADC maps inside the tumor. There was a significant correlation between ADC values and reduction ratio. When calculating the mean ADC values for three groups; more than 50%, 50–25% and less than 25%, ADC values significantly increased with increasing reduction ratio; 2.05?×?10^?3?mm²/s, 1.28?×?10^?3?mm²/s and 0.94?×?10^?3?mm²/s, respectively (p?=?0.0180). Multiple regression analysis by reduction ratio (%), ADC mean values (×10^?3?mm²/s), tumor longest diameter (cm) and CA125 (U/ml) revealed that tumor reduction ratio by DNG administration could be predicted by the following equation; R?=?19.3 + 24.0x – 0.4y + 0.1z (R: Reduction ratio, x: ADC mean, y: Longest diameter, z: CA125). In conclusion, the ADC mean value is useful for the prediction of the treatment response in ovarian endometrial cyst patients with DNG administration.     

The value of urocortin and Ca-125 in the diagnosis of endometrioma

Purposes

In this study, we sought to establish the value of a new molecule, urocortin (Ucn), in the diagnosis of endometrioma and compare with Ca-125 to identify superiority of urocortin.

Methods

Of the patients operated on at our hospital with the initial diagnosis of adnexal mass, 88 patients whose pathology results were endometrioma and benign ovarian cyst were included in the study. As a result of the pathological examination, the patients were assessed in two groups. Group 1 consisted of 42 cases of endometrioma and Group 2 included 46 cases of benign ovarian cyst (control group). The serum Ucn and CA 125 levels of patients were measured from the blood samples drawn prior to the operation.

Results

While the serum Ucn level was 4.8?±?1.00?ng/ml in the endometrioma group, it was 4.5?±?1.03?ng/ml in the control group (P?=?0.21). The difference was statistically not meaningful. On the other hand, mean serum Ca-125 level was 43.8?U/l (11.7?C251) in the endometrioma group, it was 16.5?U/l (4.3?C121.1) in the control group. The difference was statistically meaningful (P?=?0.001). When the cut-off point for Serum Ca-125 level was taken as 21.38, sensitivity and specificity levels were found to be 88.1 and 63%. When the cut-off point for Ucn was taken as 4.16, sensitivity was 76.2%, and specificity 45.7%.

Conclusion

Ucn was not found to be efficient in distinguishing endometrioma from other benign ovarian cysts or to be superior to CA125 in the diagnosis of endometrioma.     

腹腔镜下电凝和缝合止血对残留卵巢储备功能影响的对比研究

目的:对比研究腹腔镜下卵巢囊肿剥除术中残留卵巢创面采用双极电凝和缝合止血方法对卵巢储备功能的影响。方法:双侧卵巢囊肿患者90例,卵巢囊肿均位于卵巢门部位以外。随机分为电凝组(45例)和缝合组(45例)。比较两组患者术后的血清E2、FSH、LH以及窦卵泡计数(AFC)的变化情况。结果:全部患者均顺利完成手术,术中未发生任何并发症。两组患者术后与术前比较,E2和AFC均显著下降,FSH显著升高,差异均有统计学意义(P<0.05),而LH差异无统计学意义(P>0.05)。两组患者术后组间比较,E2、FSH以及AFC差异无统计学意义(P>0.05)。两组术后均有1例患者新发生卵巢储备功能下降,均无卵巢功能衰竭病例发生。结论:对囊肿位于卵巢门部位外的卵巢囊肿患者,腹腔镜下卵巢囊肿剥除术中,残留卵巢创面采用双极电凝和缝合止血方法对卵巢功能影响无明显差异。     

不同促排卵方案对子宫内膜异位症妊娠结局的影响因素分析

目的:了解不同促排卵方案对行体外受精-胚胎移植( IVF-ET)子宫内膜异位症(EMT)患者妊娠结局的影响.方法:回顾性分析安徽医科大学第一附属医院生殖医学中心2008年1月至2010年3月因EMT行IVF-ET共262周期的临床资料,根据超促排卵方案不同分为超长方案组、短方案组和长方案组,比较3组间年龄、不孕类型、不孕年限、降调前CA125值、基础FSH、LH、E2水平、基础窦卵泡数、Gn启动量、Gn天数、Gn总量、取卵日E2、P、LH水平、子宫内膜厚度、获卵率、优质胚胎率和临床妊娠率,以及超长方案组降调后血清CA125水平与临床妊娠率的关系.结果:①短方案组年龄大于超长方案组和长方案组(P＜0.05),而3组患者不孕类型和不孕年限比较,差异无统计学意义(P＞0.05);②短方案组基础FSH水平、Gn启动量、取卵日LH值均较超长方案组及长方案组高(P＜0.05);短方案组基础窦卵泡数、Gn天数、Gn用量、取卵日子宫内膜厚度及获卵数均少于其他两组(P＜0.05);超长方案组降调前CA125值大于短方案组及长方案组(P＜0.05).③超长方案组降调后CA125值≤10 KU/L的妊娠率(40.91％)与10～20 KU/L和＞20 KU/L水平的妊娠率(18.31％和17.65％)比较,差异有统计学意义(P＜0.05).结论:对于轻度EMT患者早期发现、早期选择辅助生殖技术治疗可以有效增加临床妊娠率,中重度患者采用超长方案同时检测血清CA125水平,对判断妊娠结局有辅助指导意义.     

Correlation between serum levels of CA 125 and follicular loss after laparoscopic cystectomy in women with ovarian endometrioma

STUDY OBJECTIVE: To preoperatively predict follicular loss after laparoscopic cystectomy of ovarian endometriomas. DESIGN: Case-control study. (Canadian Task Force classification II-2). SETTING: University hospital. PATIENTS: Seventy-six women with ovarian endometrioma and 41 patients with nonendometriotic ovarian cysts who underwent laparoscopy. INTERVENTIONS: Sonographic findings and serum levels of CA 125 and CA 19.9 were recorded. MEASUREMENTS AND MAIN RESULTS: Considered parameters were compared with a histologic score, on the basis of the presence and morphologic features of follicles on the normal ovarian tissue adjacent to the cyst wall surgically removed. Serum levels of CA 125 and CA 19.9 were increased in patients with ovarian endometrioma (p <.001 and p <.01, respectively). Capsule wall thickness, presence of fibrosis, and follicles in the tissue surrounding the capsule were significantly increased in the study group (p <.01). CA 125 serum level was directly correlated to the histologic score (r = 0.46, p <.05) and to cyst diameter (r = 0.12, p = .01), whereas no correlation was found between CA 19.9 or cyst diameter and follicular score. CONCLUSIONS: Our data suggest that the ovarian tissue inadvertently removed along with the endometrioma wall by laparoscopic stripping is due to pericystic fibrosis. Serum levels of CA 125 represent a useful parameter to predict follicular loss before surgery.     

Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats

This study hypothesizes that oral rosuvastatin, oral dienogest and intraperitoneal bevacizumab might improve endometriosis in randomly selected female Wistar albino rats with surgically endometriotic implants. Thirty female Wistar albino rats with surgically endometriotic implants were randomized into three treatment groups: oral rosuvastatin (20?mg kg/day; oral rosuvastatin group 1; n?=?10), oral progesterone (dienogest group 2; n?=?10) and intraperitoneal bevacizumab (2.5?mg/kg of single intraperitoneal injection of bevacizumab; bevacizumab group 3; n?=?10), for 10 days. Post-treatment variables were compared. The oral rosuvastatin group showed higher reduction for the glandular epithelium and uterine vessels of histopathological scores values than the oral progesterone group (both, p?p?>?0.017). Endometrial thickness values and uterine volume values were more significantly reduced in the oral rosuvastatin group than the oral progesterone group (both, p?p?>?0.017). In conclusion, oral rosuvastatin and intraperitoneal injection of bevacizumab may cause more significant regression of surgically endometriotic implants in rats than oral progesterone medications.     

Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women.

OBJECTIVE: To compare the efficacy of two different doses, 1.88 mg and 3.75 mg, of a monthly depot injection of a gonadotropin-releasing hormone agonist (GnRH-a) in the treatment of uterine leiomyomata. DESIGN: A prospective randomized study. SETTING: Hospital department of gynecology and obstetrics. PATIENTS: Forty-one premenopausal Japanese women, 25 to 53 years of age, with uterine leiomyomata. INTERVENTIONS: Depot type of GnRH-a, leuprolide acetate (LA) 1.88 mg or 3.75 mg was administered subcutaneously every 4 weeks for 24 weeks. MAIN OUTCOME MEASURES: Efficacy of treatment was assessed in terms of uterine volume, serum levels of estradiol (E2), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and adverse symptoms during treatment. RESULTS: In both groups, a significant reduction in uterine volume, 52% in 1.88 mg group and 47% in 3.75 mg group, was obtained at week 24, with near maximal reduction (41%, 45%) apparent by 12 weeks. No significant difference was observed between the groups in percent uterine volume reduction at each treatment week. Both groups showed significant and equal suppression of serum levels of E2, LH, and FSH. In addition, the incidence of adverse symptoms was not significantly different between the two groups. CONCLUSIONS: Monthly injection of 1.88 mg or 3.75 mg LA depot has equivalent treatment efficacy in reducing uterine volume. Twelve weeks of treatment is enough to obtain near maximal reduction.